GSK3 activity is known to be negatively regulated through phosphorylation at Ser 21 (α) and 9 (β) mediated by PI3K/Akt, PKC, p70S6K and RAS/ERK/RSK2 signaling, which are often hyper-activated in a variety of cancer types, [29]. This evidence concerns the gene PRRT2 and cancer.